ArticleFrontiers in immunology2026
Implications of systolic pulmonary artery pressure trajectories in systemic lupus erythematosus-associated pulmonary hypertension: a CSTAR-PAH cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To identify the evolution trajectory of systolic pulmonary artery pressure (sPAP) in patients with systemic lupus erythematosus-related pulmonary arterial hypertension (SLE-PAH) and to evaluate its prognostic significance. Method: In this study, 81 SLE-PAH patients from the Chinese SLE Treatment and Research Group-Pulmonary Arterial Hypertension (CSTAR-PAH) cohort of the Second Affiliated Hospital of Nanchang University were included for a retrospective cohort study. A group-based trajectory model was used to identify the trajectories of sPAP over time. Baseline factors related to trajectory assignment were analyzed through multiple logistic regression. Univariate and multivariate Cox regression and Kaplan-Meier analysis were used to evaluate the prognostic value of trajectory groups for all-cause mortality, and to analyze the related influencing factors of all-cause mortality. Results: Four distinct sPAP trajectories were identified: trajectory 1 (n = 17, 20.9%; high initial sPAP with rapid decrease), trajectory 2 (n = 44, 54.3%; moderate initial sPAP with slow decrease), trajectory 3 (n = 13, 16.0%; low initial sPAP with slow decrease), and trajectory 4 (n = 7, 8.6%; high initial sPAP with rapid increase). Longer 6-minute walking distance (6MWD) was independently associated with trajectories 2 (OR = 3.077, p < 0.001) and 3 (OR = 11.106, p < 0.001), whereas shorter 6MWD (OR = 0.220, p < 0.001), elevated B-type natriuretic peptide (OR = 2.159, p < 0.001), higher IL-1β (OR = 1.412, p < 0.001), higher TNF-α (OR = 1.751, p < 0.001), and higher mean pulmonary artery pressure (OR = 1.067, p < 0.001) independently predicted trajectory 4 membership. During follow-up, trajectory 4 remained a strong independent predictor of mortality (HR = 8.843, p = 0.037) after multivariable adjustment, together with higher systemic lupus erythematosus disease activity index (HR = 1.502, p = 0.032), elevated IL-6 (HR = 1.031, p=0.029), higher systemic inflammation response index (HR = 1.828, p = 0.019), and shorter 6MWD (HR = 0.795, p = 0.028). Patients in trajectory 4 exhibited significantly worse survival (log-rank p < 0.0001). Conclusion: sPAP trajectories capture clinically meaningful heterogeneity in SLE-PAH, with the rapid-progression trajectory identifying a high-risk phenotype characterized by pronounced inflammation, right ventricular strain, and functional compromise. Trajectory-based phenotyping enhances risk stratification and may guide personalized management in SLE-PAH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.